世界のトランスサイレチンアミロイドーシス（ATTR）市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Transthyretin Amyloidosis (ATTR) Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z5732 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、93ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、トランスサイレチンアミロイドーシス（ATTR）のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（遺伝性ATTR（HATTR）、野生型（WT）ATTR）、用途別市場規模（病院、外来手術センター、診断センター）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・トランスサイレチンアミロイドーシス（ATTR）の市場動向 ・企業の競争状況、市場シェア ・トランスサイレチンアミロイドーシス（ATTR）の種類別市場規模（遺伝性ATTR（HATTR）、野生型（WT）ATTR） ・トランスサイレチンアミロイドーシス（ATTR）の用途別市場規模（病院、外来手術センター、診断センター） ・トランスサイレチンアミロイドーシス（ATTR）の北米市場規模2016-2027（アメリカ、カナダ） ・トランスサイレチンアミロイドーシス（ATTR）のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・トランスサイレチンアミロイドーシス（ATTR）のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・トランスサイレチンアミロイドーシス（ATTR）の中南米市場規模2016-2027（メキシコ、ブラジル） ・トランスサイレチンアミロイドーシス（ATTR）の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Pfizer、Alnylam Pharmaceuticals、Ionis Pharmaceuticals、Corino Therapeutics、Proclara Bioscience、Arcturus Therapeutics） ・結論

Transthyretin Amyloidosis (ATTR) is an autosomal dominant hereditary disease that occurs due to deposition of variant TTR (transthyretin) protein in humans. It is mainly characterized into two main types i.e. Hereditary ATTR (hATTR) and Wild-Type (wt) ATTR. While Hereditary ATTR is caused by point mutations within TTR allele, wild-type ATTR is caused by the misfolding of Wild-Type TTR. Major prevalence of Hereditary ATTR is observed in the 7MM, and this type has been further sub-classified into Familial Amyloidosis Polyneuropathy (FAP) and Familial Amyloidosis Cardiomyopathy (FAC).
United States accounts for highest ATTR Amyloidosis Cases, followed by EU5 (Italy, France, Spain, Germany, UK) and Japan.

Market Analysis and Insights: Global Transthyretin Amyloidosis (ATTR) Market
The global Transthyretin Amyloidosis (ATTR) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Transthyretin Amyloidosis (ATTR) market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Transthyretin Amyloidosis (ATTR) market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Transthyretin Amyloidosis (ATTR) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Transthyretin Amyloidosis (ATTR) market.

Global Transthyretin Amyloidosis (ATTR) Scope and Market Size
Transthyretin Amyloidosis (ATTR) market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Transthyretin Amyloidosis (ATTR) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Hereditary ATTR (HATTR)
Wild-Type (WT) ATTR

Segment by Application
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Pfizer
Alnylam Pharmaceuticals
Ionis Pharmaceuticals
Corino Therapeutics
Proclara Bioscience
Arcturus Therapeutics

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Transthyretin Amyloidosis (ATTR) Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Hereditary ATTR (HATTR)
1.2.3 Wild-Type (WT) ATTR
1.3 Market by Application
1.3.1 Global Transthyretin Amyloidosis (ATTR) Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Diagnostic Centers
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Transthyretin Amyloidosis (ATTR) Market Perspective (2016-2027)
2.2 Transthyretin Amyloidosis (ATTR) Growth Trends by Regions
2.2.1 Transthyretin Amyloidosis (ATTR) Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Transthyretin Amyloidosis (ATTR) Historic Market Share by Regions (2016-2021)
2.2.3 Transthyretin Amyloidosis (ATTR) Forecasted Market Size by Regions (2022-2027)
2.3 Transthyretin Amyloidosis (ATTR) Industry Dynamic
2.3.1 Transthyretin Amyloidosis (ATTR) Market Trends
2.3.2 Transthyretin Amyloidosis (ATTR) Market Drivers
2.3.3 Transthyretin Amyloidosis (ATTR) Market Challenges
2.3.4 Transthyretin Amyloidosis (ATTR) Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Transthyretin Amyloidosis (ATTR) Players by Revenue
3.1.1 Global Top Transthyretin Amyloidosis (ATTR) Players by Revenue (2016-2021)
3.1.2 Global Transthyretin Amyloidosis (ATTR) Revenue Market Share by Players (2016-2021)
3.2 Global Transthyretin Amyloidosis (ATTR) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Transthyretin Amyloidosis (ATTR) Revenue
3.4 Global Transthyretin Amyloidosis (ATTR) Market Concentration Ratio
3.4.1 Global Transthyretin Amyloidosis (ATTR) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Transthyretin Amyloidosis (ATTR) Revenue in 2020
3.5 Transthyretin Amyloidosis (ATTR) Key Players Head office and Area Served
3.6 Key Players Transthyretin Amyloidosis (ATTR) Product Solution and Service
3.7 Date of Enter into Transthyretin Amyloidosis (ATTR) Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Transthyretin Amyloidosis (ATTR) Breakdown Data by Type
4.1 Global Transthyretin Amyloidosis (ATTR) Historic Market Size by Type (2016-2021)
4.2 Global Transthyretin Amyloidosis (ATTR) Forecasted Market Size by Type (2022-2027)

5 Transthyretin Amyloidosis (ATTR) Breakdown Data by Application
5.1 Global Transthyretin Amyloidosis (ATTR) Historic Market Size by Application (2016-2021)
5.2 Global Transthyretin Amyloidosis (ATTR) Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Transthyretin Amyloidosis (ATTR) Market Size (2016-2027)
6.2 North America Transthyretin Amyloidosis (ATTR) Market Size by Type
6.2.1 North America Transthyretin Amyloidosis (ATTR) Market Size by Type (2016-2021)
6.2.2 North America Transthyretin Amyloidosis (ATTR) Market Size by Type (2022-2027)
6.2.3 North America Transthyretin Amyloidosis (ATTR) Market Size by Type (2016-2027)
6.3 North America Transthyretin Amyloidosis (ATTR) Market Size by Application
6.3.1 North America Transthyretin Amyloidosis (ATTR) Market Size by Application (2016-2021)
6.3.2 North America Transthyretin Amyloidosis (ATTR) Market Size by Application (2022-2027)
6.3.3 North America Transthyretin Amyloidosis (ATTR) Market Size by Application (2016-2027)
6.4 North America Transthyretin Amyloidosis (ATTR) Market Size by Country
6.4.1 North America Transthyretin Amyloidosis (ATTR) Market Size by Country (2016-2021)
6.4.2 North America Transthyretin Amyloidosis (ATTR) Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Transthyretin Amyloidosis (ATTR) Market Size (2016-2027)
7.2 Europe Transthyretin Amyloidosis (ATTR) Market Size by Type
7.2.1 Europe Transthyretin Amyloidosis (ATTR) Market Size by Type (2016-2021)
7.2.2 Europe Transthyretin Amyloidosis (ATTR) Market Size by Type (2022-2027)
7.2.3 Europe Transthyretin Amyloidosis (ATTR) Market Size by Type (2016-2027)
7.3 Europe Transthyretin Amyloidosis (ATTR) Market Size by Application
7.3.1 Europe Transthyretin Amyloidosis (ATTR) Market Size by Application (2016-2021)
7.3.2 Europe Transthyretin Amyloidosis (ATTR) Market Size by Application (2022-2027)
7.3.3 Europe Transthyretin Amyloidosis (ATTR) Market Size by Application (2016-2027)
7.4 Europe Transthyretin Amyloidosis (ATTR) Market Size by Country
7.4.1 Europe Transthyretin Amyloidosis (ATTR) Market Size by Country (2016-2021)
7.4.2 Europe Transthyretin Amyloidosis (ATTR) Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Size (2016-2027)
8.2 Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Size by Type
8.2.1 Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Size by Type (2016-2027)
8.3 Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Size by Application
8.3.1 Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Size by Application (2016-2027)
8.4 Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Size by Region
8.4.1 Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Transthyretin Amyloidosis (ATTR) Market Size (2016-2027)
9.2 Latin America Transthyretin Amyloidosis (ATTR) Market Size by Type
9.2.1 Latin America Transthyretin Amyloidosis (ATTR) Market Size by Type (2016-2021)
9.2.2 Latin America Transthyretin Amyloidosis (ATTR) Market Size by Type (2022-2027)
9.2.3 Latin America Transthyretin Amyloidosis (ATTR) Market Size by Type (2016-2027)
9.3 Latin America Transthyretin Amyloidosis (ATTR) Market Size by Application
9.3.1 Latin America Transthyretin Amyloidosis (ATTR) Market Size by Application (2016-2021)
9.3.2 Latin America Transthyretin Amyloidosis (ATTR) Market Size by Application (2022-2027)
9.3.3 Latin America Transthyretin Amyloidosis (ATTR) Market Size by Application (2016-2027)
9.4 Latin America Transthyretin Amyloidosis (ATTR) Market Size by Country
9.4.1 Latin America Transthyretin Amyloidosis (ATTR) Market Size by Country (2016-2021)
9.4.2 Latin America Transthyretin Amyloidosis (ATTR) Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Size (2016-2027)
10.2 Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Size by Type
10.2.1 Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Size by Type (2016-2027)
10.3 Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Size by Application
10.3.1 Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Size by Application (2016-2027)
10.4 Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Size by Country
10.4.1 Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Transthyretin Amyloidosis (ATTR) Introduction
11.1.4 Pfizer Revenue in Transthyretin Amyloidosis (ATTR) Business (2016-2021)
11.1.5 Pfizer Recent Development
11.2 Alnylam Pharmaceuticals
11.2.1 Alnylam Pharmaceuticals Company Details
11.2.2 Alnylam Pharmaceuticals Business Overview
11.2.3 Alnylam Pharmaceuticals Transthyretin Amyloidosis (ATTR) Introduction
11.2.4 Alnylam Pharmaceuticals Revenue in Transthyretin Amyloidosis (ATTR) Business (2016-2021)
11.2.5 Alnylam Pharmaceuticals Recent Development
11.3 Ionis Pharmaceuticals
11.3.1 Ionis Pharmaceuticals Company Details
11.3.2 Ionis Pharmaceuticals Business Overview
11.3.3 Ionis Pharmaceuticals Transthyretin Amyloidosis (ATTR) Introduction
11.3.4 Ionis Pharmaceuticals Revenue in Transthyretin Amyloidosis (ATTR) Business (2016-2021)
11.3.5 Ionis Pharmaceuticals Recent Development
11.4 Corino Therapeutics
11.4.1 Corino Therapeutics Company Details
11.4.2 Corino Therapeutics Business Overview
11.4.3 Corino Therapeutics Transthyretin Amyloidosis (ATTR) Introduction
11.4.4 Corino Therapeutics Revenue in Transthyretin Amyloidosis (ATTR) Business (2016-2021)
11.4.5 Corino Therapeutics Recent Development
11.5 Proclara Bioscience
11.5.1 Proclara Bioscience Company Details
11.5.2 Proclara Bioscience Business Overview
11.5.3 Proclara Bioscience Transthyretin Amyloidosis (ATTR) Introduction
11.5.4 Proclara Bioscience Revenue in Transthyretin Amyloidosis (ATTR) Business (2016-2021)
11.5.5 Proclara Bioscience Recent Development
11.6 Arcturus Therapeutics
11.6.1 Arcturus Therapeutics Company Details
11.6.2 Arcturus Therapeutics Business Overview
11.6.3 Arcturus Therapeutics Transthyretin Amyloidosis (ATTR) Introduction
11.6.4 Arcturus Therapeutics Revenue in Transthyretin Amyloidosis (ATTR) Business (2016-2021)
11.6.5 Arcturus Therapeutics Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Transthyretin Amyloidosis (ATTR) Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Hereditary ATTR (HATTR)
Table 3. Key Players of Wild-Type (WT) ATTR
Table 4. Global Transthyretin Amyloidosis (ATTR) Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Transthyretin Amyloidosis (ATTR) Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Transthyretin Amyloidosis (ATTR) Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Transthyretin Amyloidosis (ATTR) Market Share by Regions (2016-2021)
Table 8. Global Transthyretin Amyloidosis (ATTR) Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Transthyretin Amyloidosis (ATTR) Market Share by Regions (2022-2027)
Table 10. Transthyretin Amyloidosis (ATTR) Market Trends
Table 11. Transthyretin Amyloidosis (ATTR) Market Drivers
Table 12. Transthyretin Amyloidosis (ATTR) Market Challenges
Table 13. Transthyretin Amyloidosis (ATTR) Market Restraints
Table 14. Global Transthyretin Amyloidosis (ATTR) Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Transthyretin Amyloidosis (ATTR) Market Share by Players (2016-2021)
Table 16. Global Top Transthyretin Amyloidosis (ATTR) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Transthyretin Amyloidosis (ATTR) as of 2020)
Table 17. Ranking of Global Top Transthyretin Amyloidosis (ATTR) Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Transthyretin Amyloidosis (ATTR) Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Transthyretin Amyloidosis (ATTR) Product Solution and Service
Table 21. Date of Enter into Transthyretin Amyloidosis (ATTR) Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Transthyretin Amyloidosis (ATTR) Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Transthyretin Amyloidosis (ATTR) Revenue Market Share by Type (2016-2021)
Table 25. Global Transthyretin Amyloidosis (ATTR) Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Transthyretin Amyloidosis (ATTR) Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Transthyretin Amyloidosis (ATTR) Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Transthyretin Amyloidosis (ATTR) Revenue Market Share by Application (2016-2021)
Table 29. Global Transthyretin Amyloidosis (ATTR) Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Transthyretin Amyloidosis (ATTR) Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Transthyretin Amyloidosis (ATTR) Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Transthyretin Amyloidosis (ATTR) Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Transthyretin Amyloidosis (ATTR) Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Transthyretin Amyloidosis (ATTR) Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Transthyretin Amyloidosis (ATTR) Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Transthyretin Amyloidosis (ATTR) Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Transthyretin Amyloidosis (ATTR) Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Transthyretin Amyloidosis (ATTR) Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Transthyretin Amyloidosis (ATTR) Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Transthyretin Amyloidosis (ATTR) Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Transthyretin Amyloidosis (ATTR) Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Transthyretin Amyloidosis (ATTR) Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Transthyretin Amyloidosis (ATTR) Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Transthyretin Amyloidosis (ATTR) Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Transthyretin Amyloidosis (ATTR) Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Transthyretin Amyloidosis (ATTR) Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Transthyretin Amyloidosis (ATTR) Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Transthyretin Amyloidosis (ATTR) Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Size by Country (2022-2027) & (US$ Million)
Table 61. Pfizer Company Details
Table 62. Pfizer Business Overview
Table 63. Pfizer Transthyretin Amyloidosis (ATTR) Product
Table 64. Pfizer Revenue in Transthyretin Amyloidosis (ATTR) Business (2016-2021) & (US$ Million)
Table 65. Pfizer Recent Development
Table 66. Alnylam Pharmaceuticals Company Details
Table 67. Alnylam Pharmaceuticals Business Overview
Table 68. Alnylam Pharmaceuticals Transthyretin Amyloidosis (ATTR) Product
Table 69. Alnylam Pharmaceuticals Revenue in Transthyretin Amyloidosis (ATTR) Business (2016-2021) & (US$ Million)
Table 70. Alnylam Pharmaceuticals Recent Development
Table 71. Ionis Pharmaceuticals Company Details
Table 72. Ionis Pharmaceuticals Business Overview
Table 73. Ionis Pharmaceuticals Transthyretin Amyloidosis (ATTR) Product
Table 74. Ionis Pharmaceuticals Revenue in Transthyretin Amyloidosis (ATTR) Business (2016-2021) & (US$ Million)
Table 75. Ionis Pharmaceuticals Recent Development
Table 76. Corino Therapeutics Company Details
Table 77. Corino Therapeutics Business Overview
Table 78. Corino Therapeutics Transthyretin Amyloidosis (ATTR) Product
Table 79. Corino Therapeutics Revenue in Transthyretin Amyloidosis (ATTR) Business (2016-2021) & (US$ Million)
Table 80. Corino Therapeutics Recent Development
Table 81. Proclara Bioscience Company Details
Table 82. Proclara Bioscience Business Overview
Table 83. Proclara Bioscience Transthyretin Amyloidosis (ATTR) Product
Table 84. Proclara Bioscience Revenue in Transthyretin Amyloidosis (ATTR) Business (2016-2021) & (US$ Million)
Table 85. Proclara Bioscience Recent Development
Table 86. Arcturus Therapeutics Company Details
Table 87. Arcturus Therapeutics Business Overview
Table 88. Arcturus Therapeutics Transthyretin Amyloidosis (ATTR) Product
Table 89. Arcturus Therapeutics Revenue in Transthyretin Amyloidosis (ATTR) Business (2016-2021) & (US$ Million)
Table 90. Arcturus Therapeutics Recent Development
Table 91. Research Programs/Design for This Report
Table 92. Key Data Information from Secondary Sources
Table 93. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Transthyretin Amyloidosis (ATTR) Market Share by Type: 2020 VS 2027
Figure 2. Hereditary ATTR (HATTR) Features
Figure 3. Wild-Type (WT) ATTR Features
Figure 4. Global Transthyretin Amyloidosis (ATTR) Market Share by Application: 2020 VS 2027
Figure 5. Hospitals Case Studies
Figure 6. Ambulatory Surgical Centers Case Studies
Figure 7. Diagnostic Centers Case Studies
Figure 8. Transthyretin Amyloidosis (ATTR) Report Years Considered
Figure 9. Global Transthyretin Amyloidosis (ATTR) Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 10. Global Transthyretin Amyloidosis (ATTR) Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Transthyretin Amyloidosis (ATTR) Market Share by Regions: 2020 VS 2027
Figure 12. Global Transthyretin Amyloidosis (ATTR) Market Share by Regions (2022-2027)
Figure 13. Global Transthyretin Amyloidosis (ATTR) Market Share by Players in 2020
Figure 14. Global Top Transthyretin Amyloidosis (ATTR) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Transthyretin Amyloidosis (ATTR) as of 2020
Figure 15. The Top 10 and 5 Players Market Share by Transthyretin Amyloidosis (ATTR) Revenue in 2020
Figure 16. Global Transthyretin Amyloidosis (ATTR) Revenue Market Share by Type (2016-2021)
Figure 17. Global Transthyretin Amyloidosis (ATTR) Revenue Market Share by Type (2022-2027)
Figure 18. North America Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 19. North America Transthyretin Amyloidosis (ATTR) Market Share by Type (2016-2027)
Figure 20. North America Transthyretin Amyloidosis (ATTR) Market Share by Application (2016-2027)
Figure 21. North America Transthyretin Amyloidosis (ATTR) Market Share by Country (2016-2027)
Figure 22. United States Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Canada Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Transthyretin Amyloidosis (ATTR) Market Share by Type (2016-2027)
Figure 26. Europe Transthyretin Amyloidosis (ATTR) Market Share by Application (2016-2027)
Figure 27. Europe Transthyretin Amyloidosis (ATTR) Market Share by Country (2016-2027)
Figure 28. Germany Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. France Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. U.K. Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Italy Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Russia Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Nordic Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Share by Type (2016-2027)
Figure 36. Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Share by Application (2016-2027)
Figure 37. Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Share by Region (2016-2027)
Figure 38. China Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Japan Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. South Korea Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Southeast Asia Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. India Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Australia Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Transthyretin Amyloidosis (ATTR) Market Share by Type (2016-2027)
Figure 46. Latin America Transthyretin Amyloidosis (ATTR) Market Share by Application (2016-2027)
Figure 47. Latin America Transthyretin Amyloidosis (ATTR) Market Share by Country (2016-2027)
Figure 48. Mexico Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Brazil Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Share by Type (2016-2027)
Figure 52. Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Share by Application (2016-2027)
Figure 53. Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Share by Country (2016-2027)
Figure 54. Turkey Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Saudi Arabia Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. UAE Transthyretin Amyloidosis (ATTR) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Pfizer Revenue Growth Rate in Transthyretin Amyloidosis (ATTR) Business (2016-2021)
Figure 58. Alnylam Pharmaceuticals Revenue Growth Rate in Transthyretin Amyloidosis (ATTR) Business (2016-2021)
Figure 59. Ionis Pharmaceuticals Revenue Growth Rate in Transthyretin Amyloidosis (ATTR) Business (2016-2021)
Figure 60. Corino Therapeutics Revenue Growth Rate in Transthyretin Amyloidosis (ATTR) Business (2016-2021)
Figure 61. Proclara Bioscience Revenue Growth Rate in Transthyretin Amyloidosis (ATTR) Business (2016-2021)
Figure 62. Arcturus Therapeutics Revenue Growth Rate in Transthyretin Amyloidosis (ATTR) Business (2016-2021)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed

---